SpringWorks Therapeutics, Inc. (SWTX): $46.23
Market Cap: $3.47 B
Deal Value: $3.4 B
Germany’s Merck KGaA entered a merger agreement on April 28, 2025, to acquire U.S.-based SpringWorks Therapeutics in an all-cash deal valued at $3.4 billion.
Under the terms of the agreement, Merck KGaA will acquire SpringWorks for $47 per share in cash, representing a premium of 5.1% from the stock’s last close. The deal represents an equity value of about $3.9 billion, or an enterprise value of $3.4 billion, when SpringWorks’ cash holdings are deducted.